Equity
€3.0m ▲ 2.5%
ZAMBON paid out €1.4m in dividends. That is 95% of the 2025 profit.
ZAMBON
Lifetime
19 annual accounts with figures on one time axis, 49 filings since 1977peak €25.1m (2018)
€18.8m▼ 1.3%
lowest -€1.0m (2020)
€1.5m▲ 0.3%
peak €3.0m (2025)
€3.0m▲ 2.5%
€4.7m▼ 2.2%
peak 56.6 FTE (2007)
20.8 FTE▼ 8.0%
Board23 names since 2005all names
4 directors and 3 others
Owners
Documentsfilings and deeds
07-05-202685 days before the deadline
2025financial year
Deed on the board 24-01Dividend €1.4m
Key points
from the 2025 annual accountsChecked score
Bankruptcy probability within 12 months
Financial strength
Score breakdown
Comparable companies, two years later
In July 2024, 20,124 companies had the same profile as ZAMBON has now. Each dot stands for 51 companies, two years later.
95.1%
were still trading
4.7%
stopped another way
0.2%
went bankrupt
Test of the method
The method was tested on the 497,331 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 2.9% | 3.1% |
| 10 | 5.6% | 6.1% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 20,124 companies, not a prediction for ZAMBON. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Board and ownership
Director
Director, since 19-12-2024
Director, since 19-12-2024
Director, since 03-04-2025
Auditor,
- consolidatesannual accounts 2020
Recent changes
1 statutory auditor appointed, 1 resignation, 1 director reappointed
Reappointment: · Resignation: (statutory auditor) · Appointment: ) (statutory auditor) · General meeting of 03-04-2025 · Gazette deed
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0403069741
Deed on the board
Gazette deed
Resignation: (director)
Appointment: (director) · General meeting of 30-06-2022 · Gazette deed
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| ZAMBON Jette | €18.8m | 10.2% | 38.5% | 20.8 |
| TELEFLEX MEDICAL Brussels | €18.7m | 3.2% | 40.9% | 16.8 |
| Revogan Ghent | €17.8m | 3.2% | 42.1% | 21.5 |
| LAGAE JOZEF EN ZONEN - VLASHANDEL EN - NIJVERHEID - LAGAE JOSEPH ET FILS - COMMERCE ET INDUSTRIE DU LIN Kuurne | €16.5m | -0.2% | 10.0% | 25.1 |
| Ceres Pharmaceuticals Ghent | €14.6m | 24.6% | 13.9% | 17.6 |
| DECHRA VETERINARY PRODUCTS Herentals | €20.5m | 3.3% | 12.0% | 15.9 |
| Crocodile Kortrijk | €24.2m | -2.1% | 82.5% | 26.7 |
Grey: the largest companies of the sector (wholesale trade (NACE 46)), without their names. Blue: the sector peers from the table.
These companies have the same main activity as ZAMBON: wholesale of pharmaceutical and medical goods (NACE 46460). They are comparable in size and age: total assets between €5.5m and €9.5m, founded between 1952 and 1971.
Official details
Source: KBO- Status
- Active since 19-07-1965Normal situation
- Registered office
- 15 active companies are registered at this addressSource: KBO register, as of 12 November 2026.
- Activity
- Wholesale of pharmaceutical and medical goodsNACE 46460
- Establishment unit
- 2.000.634.0071090 Jette, since 01-07-1965
- Financial year end
- 31 December
- Peppol
- Reachable since 31-12-2025
Annual accounts 2025
- €7.7m▼ 0.4%
- Employeeson 31-12-2025
- 22▼ 4.3%
- Filing
- Filed on 07-05-2026, 85 days before the end of the filing period
Insights on ZAMBON
ZAMBON has been active since 1965 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €3.0m and a net result of €1.5m.
Equity has been growing by about 8.8% per year since 2018. Its solvency ranks better than 44% of 3,761 sector peers (NACE 46, financial year 2025).
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about ZAMBON
- What is the company number of ZAMBON?
- The company number of ZAMBON is 0403.069.741. The VAT number is the same number with BE in front: BE 0403.069.741.
- Where is ZAMBON based?
- The registered office is at Burgemeester Etienne Demunterl. 3, 1090 Jette.Company details
- What does ZAMBON do?
- According to the KBO register, the main activity is wholesale of pharmaceutical and medical goods (NACE 46460).
- What is the legal form of ZAMBON?
- ZAMBON is a public limited company (NV).
- When was ZAMBON founded?
- ZAMBON was founded on 19-07-1965.
- Is ZAMBON still active?
- Yes, ZAMBON is an active enterprise in the KBO register.
- How many employees does ZAMBON have?
- ZAMBON had an average of 20.8 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- What is the turnover of ZAMBON?
- The turnover of ZAMBON was €18.8m in financial year 2025, according to the filed annual accounts.
- Is ZAMBON profitable?
- In financial year 2025, ZAMBON made a profit of €1.5m.
- Where can I find the annual accounts of ZAMBON?
- ZAMBON filed 49 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of ZAMBON due?
- ZAMBON must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence See whether the workforce is growing and whether people stay.Employer check Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark
See how customers, suppliers and banks see your own company and what to improve first.